Table 2 HIV seropositivity in relation to some selected participant characteristics (N = 74)
Characteristic | HIV serostatus | Total | p-value | |
|---|---|---|---|---|
Positive | Negative | |||
Age group | ||||
≤50 years | 19 (50.0) | 19 (50.0) | 38 (100.0) | <0.001 (Pearson)* |
>50 years | 3 (8.3) | 33 (91.7) | 36 (100.0) | |
Sub-total | 22 (29.7) | 52 (70.3) | 74 (100.0) | |
Clinical stage | ||||
Stage IB | 5 (20.8) | 19 (79.2) | 24 (100.0) | |
Stage IIA | 4 (26.7) | 11 (73.3) | 15 (100.0) | |
Stage IIB | 4 (36.4) | 7 (63.6) | 11 (100.0) | |
Stage IIIA | 3 (50.0) | 3 (50.0) | 6 (100.0) | |
Stage IIIB | 4 (40.0) | 6 (60.0) | 10 (100.0) | |
Stage IVA | 2 (25.0) | 6 (75.0) | 8 (100.0) | |
Total | 22 (29.7) | 52 (70.3) | 74 (100.0) | |
Stage classification | ||||
Early stage (IA-IIA) | 9 (23.1) | 30 (76.6) | 39 (100.0) | 0.186 (Pearson)** |
Advanced stage (IIB-IVB) | 13 (37.1) | 22 (62.9) | 35 (100.0) | |
Total | 22 (29.7) | 52 (70.3) | 74 (100.0) | |
Tumor cell differentiation | ||||
Well | 12 (52.2) | 11 (47.8) | 23 (100.0) | 0.006 (exact)*** |
Moderate | 8 (25.8) | 23 (74.4) | 31 (100.0) | |
Poor | 2 (11.1) | 16 (88.9) | 18 (100.0) | |
Total | 22 (30.6) | 50 (69.4) | 72 (100.0)**** | |